Yes, treat hypomagnesemia in patients on pembrolizumab (Keytruda) and cetuximab—magnesium replacement is safe and necessary, and neither therapy needs to be discontinued.
Magnesium replacement should be initiated when serum magnesium falls below 1.8 mg/dL (1.5 mEq/L), ideally before levels drop below 1.1 mg/dL, to prevent severe hypomagnesemia and its complications. 1, 2
Understanding the Problem
Cetuximab is the primary culprit here—it causes hypomagnesemia in up to 55% of patients through renal magnesium wasting by blocking EGFR in the distal convoluted tubule 3. The incidence of severe (grade 3/4) hypomagnesemia increases with treatment duration: 6% at <3 months, 23% at 3-6 months, and 47% at >6 months 4. Pembrolizumab does not directly cause hypomagnesemia, so the combination doesn't create additive risk beyond what cetuximab alone causes.
When to Start Replacement
Initiate magnesium supplementation at Grade 1 hypomagnesemia (serum Mg <1.8 mg/dL but ≥1.2 mg/dL) 2, 5. This proactive approach significantly reduces progression to severe hypomagnesemia. Research shows that early supplementation at Grade 1 reduces the rate of deterioration to Grade 3+ from 60% to 6.3% 5.
Replacement Strategy
For Mild-Moderate Hypomagnesemia (Grade 1-2):
- Start with IV magnesium sulfate 20 mL (20 mEq) given as a slow infusion
- If levels continue to decline despite supplementation, increase to 40 mL (40 mEq) 5
- Oral supplementation (250-500 mg elemental magnesium daily) is generally ineffective for cetuximab-induced hypomagnesemia 6, 4
For Severe Hypomagnesemia (Grade 3-4, <1.2 mg/dL):
- IV magnesium sulfate 1-2 g (8-16 mEq) bolus over 10-20 minutes for symptomatic patients 7, 8
- Follow with maintenance: 6-10 g per dose, given daily to three times weekly 4
- Consider continuous magnesium infusions (starting at 10 mmol/day, up-titrated as needed) for refractory cases 9
Monitoring Protocol
- Check serum magnesium before each cetuximab dose 10
- Also monitor calcium, phosphate, and potassium, as hypomagnesemia can cause secondary hypocalcemia and hypokalemia 11, 12
- Correct magnesium first before attempting to correct calcium or potassium, as these won't normalize until magnesium is repleted 11
- Monitor for QT prolongation on EKG, especially if magnesium <1.2 mg/dL 7
Critical Pitfalls to Avoid
Do not rely on oral magnesium alone—cetuximab-induced hypomagnesemia is refractory to oral supplementation due to ongoing renal wasting 4. The gastrointestinal side effects of oral magnesium (diarrhea) also limit tolerability.
Do not discontinue either pembrolizumab or cetuximab for hypomagnesemia alone—this is a manageable toxicity that responds to replacement 1, 13. Only consider dose interruption if hypomagnesemia becomes refractory to aggressive IV replacement or causes life-threatening arrhythmias.
Recognize that hypomagnesemia persists during treatment—expect to continue IV magnesium supplementation throughout cetuximab therapy. Recovery typically occurs approximately 4 weeks after cetuximab discontinuation 4.
Clinical Significance
Untreated hypomagnesemia can cause serious complications including cardiac arrhythmias (particularly torsades de pointes), seizures, muscle weakness, and neuropsychiatric symptoms 1, 7. The combination of checkpoint inhibitors with chemotherapy already carries increased toxicity risk 14, making proactive electrolyte management essential.
The order of treatment is straightforward: replace magnesium aggressively with IV supplementation while continuing both cancer therapies, monitoring levels before each cetuximab dose, and adjusting replacement doses based on response.